NCT04310631 is a clinical trial of Ranibizumab Injection in Coats Disease, sponsored by Federico II University.

Who is sponsoring NCT04310631?

NCT04310631 is sponsored by Federico II University.

What drugs are being tested in NCT04310631?

Interventions in NCT04310631: Ranibizumab Injection.

What condition does NCT04310631 study?

NCT04310631 studies Coats Disease.

Is NCT04310631 still recruiting?

NCT04310631 is currently completed. Last updated 17 March 2020.

Last reviewed 2020-03-17 · How we verify

NCT04310631

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of Retinal and Vascular Features in Coats Disease After Intravitreal Injections of Ranibizumab

Completed Last updated 17 March 2020

What this trial tests

trial testing Ranibizumab Injection in Coats Disease in 5 participants. Completed in 31 December 2019.

Timeline

1 January 2016

Primary endpoint
31 December 2019

31 December 2019

Quick facts

Lead sponsor	Federico II University
Status	Completed
Study type	OBSERVATIONAL
Enrollment	5
Start date	1 January 2016
Primary completion	31 December 2019
Estimated completion	31 December 2019
Sites	1 location across Italy

Drugs / interventions tested

Ranibizumab Injection — full drug profile →

Conditions studied

Coats Disease — all drugs for Coats Disease →

Sponsor

Federico II University

Who can join

Adults 19 to 30, male only, with Coats Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study evaluates the retinal and vascular features in patients affected by Coats disease under the effects of Ranibizumab intravitreal injections using optical coherence tomography and optical coherence tomography angiography

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Optical Coherence Tomography Angiography Findings After Intravitreal Ranibizumab in Patients With Coats Disease.
Cennamo G, Montorio D, Comune C, Laezza MP, et al · · 2020 · cited 7× · PMID 33585512 · DOI 10.3389/fmed.2020.615015
Retinal Vascular Changes in Radiation Maculopathy after Intravitreal Ranibizumab by Optical Coherence Tomography Angiography.
Cennamo G, Montorio D, Bernardo R, Farella A, et al · · 2020 · cited 6× · PMID 32471149 · DOI 10.3390/jcm9061618

Verify or expand the search:

Other trials of Ranibizumab Injection

Trials testing the same drug.

NCT05248334 — A Prospective Study of Ranibizumab in the Treatment of Postoperative Recurrent Vitreous Haemorrhage of Diabetic Retinopa · Phase 1 · unknown
NCT04444492 — Combination of Ranibizumab and Targeted Laser Photocoagulation · Phase 3 · recruiting
NCT03999125 — Anti-VEGF Therapy Versus Dexamethasone Implant for DME · Phase 4 · unknown
NCT04714242 — OCTA and Polypoidal Choroidal Vasculopathy · completed
NCT03385382 — Ranibizumab Versus Dexamethasone Implant in Diabetic Macular Edema · completed

Other recruiting trials for Coats Disease

Currently open trials in the same condition.

NCT06520410 — Safety and Efficacy of 18 mm Short Vitrectomy Probe for Pediatric Vitreoretinal Surgeries · Phase 4 · recruiting

Other Federico II University trials

Trials by the same sponsor.

NCT07437690 — Fall Prevention in Older Adults in an Italian Cohort · not yet recruiting
NCT07282132 — Evaluation of Real-World Data on Ropeginterferon Alfa-2b in Patients With Polycythemia Vera: Insights From a Multicenter · not yet recruiting
NCT07280286 — Incidence of Intrauterine Adhesions After Myomectomy With Intrauterine Anti-Adhesion Gel · NA · not yet recruiting
NCT07374861 — Multicenter Study on the Evaluation of Adherence, Persistence and Efficacy of Treatment With Bempedoic Acid in Italy · recruiting
NCT07314684 — GLP1-RAs Effects on Inflammatory and Endothelial Biomarkers in T2DM · Phase 4 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04310631 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Federico II University
Last refreshed: 17 March 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04310631.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing